PMCB Key Statistics, Chart & Performance
The current stock price of PMCB is 0.7101 USD. In the past month the price decreased by -13.79%. In the past year, price decreased by -54.78%.
PMCB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About PMCB
Company Profile
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Company Info
PHARMACYTE BIOTECH INC
3960 Howard Hughes Parkway, Suite 500
Las Vegas NEVADA US
CEO: Kenneth L. Waggoner
Employees: 2
Phone: 19175952850
PHARMACYTE BIOTECH INC / PMCB FAQ
What does PMCB do?
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
What is the stock price of PHARMACYTE BIOTECH INC today?
The current stock price of PMCB is 0.7101 USD. The price decreased by -7.18% in the last trading session.
Does PHARMACYTE BIOTECH INC pay dividends?
PMCB does not pay a dividend.
What is the ChartMill technical and fundamental rating of PMCB stock?
PMCB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Who owns PHARMACYTE BIOTECH INC?
You can find the ownership structure of PHARMACYTE BIOTECH INC (PMCB) on the Ownership tab.
PMCB Technical Analysis
PMCB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PMCB. No worries on liquidiy or solvency for PMCB as it has an excellent financial health rating, but there are worries on the profitability.
PMCB Financial Highlights
Over the last trailing twelve months PMCB reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS decreased by -152.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.8% | ||
| ROE | -8.07% | ||
| Debt/Equity | 0 |